Top

Published in:

05-08-2022 | ASO Author Reflections

ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?

Authors: Mikail Gögenur, MD, Claus Lindbjerg Andersen, PhD, Ismail Gögenur, DMSc

Published in: Annals of Surgical Oncology | Issue 13/2022

Excerpt

Neoadjuvant treatment has been adopted in the treatment of several cancers to downsize tumors and treat micrometastic disease to reduce local and distant recurrence.¹ Circulating tumor DNA (ctDNA) has been established as an accurate measure of minimal residual disease in patients undergoing surgery,^2,3 while its role in the neoadjuvant setting remains to be elucidated. …

Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46. https://doi.org/10.1056/nejmoa010580.CrossRefPubMed

Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–31. https://doi.org/10.1001/jamaoncol.2019.0528.CrossRefPubMedPubMedCentral

Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28(3):507–17. https://doi.org/10.1158/1078-0432.CCR-21-2404.CrossRefPubMed

Gögenur M, Hadi A-HH, Qvortrup C, Andersen CL, Gögenur I. ctDNA for risk of recurrence assessment in patients treated with neoadjuvant treatment: a systematic review and meta-analysis. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12366-7.CrossRefPubMed

Title: ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?
Authors: Mikail Gögenur, MD
Claus Lindbjerg Andersen, PhD
Ismail Gögenur, DMSc
Publication date: 05-08-2022
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-022-12378-3

At a glance: The STEP trials

Springer Medicine

ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2022

ASO Author Reflections: Fertility-Sparing Treatment for Early-Stage Cervical Cancer 2 cm or Larger in Size: A Problem Still Open

Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

ASO Visual Abstract: Chyle Leak After Axillary Node Clearance in Breast Cancer Surgery: A Rare Complication and a Proposed Management Strategy from the British and Italian Experience

ASO Visual Abstract: Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer

Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

Utilization of Natural Language Processing Software to Identify Worrisome Pancreatic Lesions